After receiving clearance from the Swiss Competition Commission, PHOENIX Pharma Switzerland and the Voigt Group completed the transaction to establish avosano AG, a 50:50 joint venture on April 28, 2023. This closing marks the start of the joint future of Amedis-UE AG, Voigt AG Pharma Grosshandel and Voigt Industrie Service AG under the umbrella of avosano AG.

The avosano Group will be an optimally positioned Swiss player in the pharmaceutical wholesale (market share of approx. 35 percent) and prewholesale (market share of approx. 40 percent) with an expected total turnover of approx. CHF 1.7 bn.

Homburger advises PHOENIX Pharma Switzerland on the transaction. The Homburger team is led by Frank Gerhard (Corporate / M&A) and comprises Andreas Burger (Regulatory / Competition) as well as Patrick Schmidt (Corporate / M&A), Allegra Arnold, Daniel Lütolf (both Regulatory / Competition), Angela Casey (Employment), and Fabio Gasser (Corporate / M&A).

Contact

Nanding Susso / Marketing / [email protected]

May 8, 2023